QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.049254v1 305/3/1037    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mcleod, R. L. Articles by Hey, J. A. Search for Related Content PubMed PubMed Citation Articles by Mcleod, R. L. Articles by Hey, J. A.

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Pharmacological Characterization of the Novel Histamine H₃-Receptor Antagonist N-(3,5-Dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687)

Allergy (R.L.M., C.A.R., R.E.W., G.G.M., L.V., S.M.W., R.W.E., J.A.H.), Chemistry (R.A., K.M., N.-Y.S.), and Drug Metabolism and Pharmacokinetics (M.B., Y.H., W.K.), Schering-Plough Research Institute, Kenilworth, New Jersey

We present the pharmacological and pharmacokinetic profiles of a novel histamine H₃ receptor antagonist, N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). The H₃-receptor binding K_i values for SCH 79687 were 1.9 and 13 nM in the rat and guinea pig (GP), respectively. The K_i values for SCH 79687 at histamine H₁ and H₂ receptors were greater than 1 µM. SCH 79687 showed a 41- and 82-fold binding selectivity for the H₃ receptor over _2A-adrenoceptors and imidazoline I₂, and >500-fold H₃ selectivity compared with over 60 additional receptors. The pA₂ value for SCH 79687 in the GP ileum electrical field-stimulated (EFS) contraction was 9.6 ± 0.3. Similar H₃ antagonist activity was observed in the EFS cryopreserved and fresh tissue isolated human saphenous vein (HSV) assays (pK_b = 9.4 ± 0.3 and 10.1 ± 0.4). SCH 79687 (30 nM) did not block clonidine-induced inhibition of EFS-induced contractions in HSV. SCH 79687 (ED₅₀ = 0.3 mg/kg i.v.) attenuated (R)--methylhistamine inhibition of sympathetic hypertensive responses in the GP. At the time of activity evaluation, the GP plasma SCH 79687 concentration was 25 ng/ml at the dose of 0.3 mg/kg i.v. In feline nasal studies, combined administration of SCH 79687 (3 mg/kg i.v.) and the H₁-antagonist loratadine (3 mg/kg i.v.), at individual doses that do not produce decongestion, inhibited the compound 48/80-induced congestion by 47%. The -adrenergic agonist phenylpropanolamine (PPA; 1 mg/kg i.v.) also attenuated compound 48/80 nasal responses by 42%. Unlike the H₃/H₁ combination that did not affect blood pressure (BP), PPA (1 mg/kg i.v.) significantly increased BP compared with control animals by a maximum of 31 mm Hg. Orally, SCH 79687 (10 mg/kg) plus loratadine (10 mg/kg) also produced decongestion without effects on BP. In pharmacokinetic studies, oral dosing with SCH 79687 in the rat (10 mg/kg) and monkey (3 mg/kg) achieved plasma C_max and area under the curve values greater than 1.5 and 12.1 µg · h/ml, respectively. SCH 79687 is an orally active H₃ antagonist with a good pharmacokinetic profile that, in combination with an H₁ antagonist, demonstrates decongestant efficacy comparable with oral sympathomimetic decongestants but without hypertensive liabilities.

Address correspondence to: Dr. Robbie L. McLeod, Allergy, Schering-Plough Research Institute, 2015 Galloping Hill Rd., Kenilworth, NJ 07033-0539. E-mail: robbie.mcleod{at}spcorp.com